Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1597P - Lung cancer screening: A systematic review

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cancer Prevention

Tumour Site

Thoracic Malignancies

Presenters

Maria Sanz Codina

Citation

Annals of Oncology (2020) 31 (suppl_4): S903-S913. 10.1016/annonc/annonc287

Authors

M. Sanz Codina, P. Rodríguez Taboada

Author affiliations

  • Thoracic Surgery Department, Hospital Universitari de Tarragona Joan XXIII, 43005 - Tarragona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1597P

Background

Lung cancer is the leading cause of cancer death and has a lower relative survival rate than other types of cancer. The survival rates of lung cancer at earlier stages are higher than later stages. A screening test that detects the disease at an early stage would facilitate early treatment, with the consequent mortality reduction and survival improvement. Our main objective is to determine whether screening high-risk patients with Low Dose CT (LDCT) reduces mortality and therefore it can be recommended at a population level.

Methods

We carried out a systematic review of the literature following the PRISMA criteria in the MEDLINE, EMBASE, and Isi Web of Science databases.

Results

Seven randomized clinical trials met the criteria. Due to the great heterogeneity methodology of clinical trials, we have carried out a qualitative synthesis of the studies. The National Lung Screening Trial (NLST) and The NELSON Trial have shown a significant reduction in lung cancer mortality, RR=0.84; 95% CI [0.75–0.95] and RR=0.76; 95% CI [0.61–0.94] respectively. In addition, a significant decrease in lung cancer mortality was found in the subgroup of women in the The LUSI Trial (RR = 0.31 [95% CI: 0.10–0.96]), The NELSON (RR = 0.67 [95% CI: 0.38 -1.14]), and The NLST (RR = 0.73 [95% CI: 0.60–0.9]). The NLST is the only study to show a reduction in mortality due to all causes (RR=0,93 [95% CI:0,86–0,99]). Even though a reduction in long-term lung cancer mortality has been demonstrated, screening implantation implies questions regarding false positives, the consequent diagnosis, and the risk of radiation, in addition to the added cost.

Conclusions

Randomized clinical trials evaluating the effectiveness of lung cancer screening have shown reduced mortality from lung cancer. Further research is needed to optimize the approach to LDCT screening but we argue that the implantation of screening in high-risk individuals should be implemented.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.